Pharmacogenetics of non-small cell lung cancer (NSCLC): Time to "work it out"?

Current Pharmaceutical Design

Volumn 20, Issue 24, 2014, Pages 3863-3874

  Galvani, Elena ^a   Toffalorio, Francesca ^b   Peters, Godefridus J ^a   de Pas, Tommaso ^b   Giovannetti, Elisa ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Chemotherapy; Genotype phenotype; New targeted anti EGFR agents; Novel methodologies and trials; NSCLC; Pharmacogenetics

Indexed keywords

ANTIINFECTIVE AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; PACLITAXEL; PEMETREXED; PLATINUM; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG TARGETING; EXOME; GENETIC TRAIT; GENOTYPE PHENOTYPE CORRELATION; HIGH THROUGHPUT SCREENING; HUMAN; LONG TERM SURVIVAL; LUNG NON SMALL CELL CANCER; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; METABOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PHARMACOGENETICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904015589     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660756     Document Type: Article

References (183)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013; 63(1): 11-30.
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
3. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009; 6: 259-265.
4. Zhou C, Wu YL, Chen G, Feng J, et al. Erlotinib versus chemo-therapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12(8): 735-742
5. Danesi R, Pasqualetti G, Giovannetti E, et al. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv Drug Deliv Rev 2009; 61(5): 408-417.
6. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
7. Giovannetti E, Toffalorio F, De Pas T, Peters GJ. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape? Pharmacogenomics 2012; 13: 1073-1086.
8. Mathiaux J, Le Morvan V, Pulido M, et al. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. Mol Diagn Ther 2011; 15(3): 159-166.
9. Peters GJ, Van Moorsel CJ, Lakerveld B, et al. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Int J Oncol 2006; 28(1): 237-244.
10. Sancar A. DNA repair in humans. Annu Rev Genet 1995; 29: 69-105.
11. Yu JJ, Mu C, Lee KB, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 1997; 382:13-20.
12. Chen P, Wiencke J, Aldape K, et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Bio-markers Prev 2000; 9: 843-847.
13. Wei HB, Hu J, Shang LH, et al. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer. Chin Med J (Engl) 2012; 125(16): 2902-2907.
14. Zhang ZY, Tian X, Wu R, et al. Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev 2012; 13(6): 2583-2586.
15. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44: 311-316.
16. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004; 15: 1194-1203.
17. Wei SZ, Zhan P, Shi MQ, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 2011; 28(1): 315-321.
18. Zhou C, Ren S, Zhou S, et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 2010; 40: 954-9560.
19. Gao R, Reece K, Sissung T, et al. The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mut Res 2011; 708(1-2): 21-7.
20. Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2010; 67: 101-107.
21. Tiseo M, Bordi P, Bortesi B, et al. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer 2013. doi: 10.1038/bjc.2013.127. [Epub ahead of print]
22. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
23. Bepler G, Olaussen KA, Vataire AL, et al. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol 2011; 178(1): 69-78.
24. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356(8): 800-808.
25. Roth JA, Carlson JJ. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer 2011; 12(6): 393-401.
26. Chen S, Zhang J, Wang R, et al. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 2010; 70: 63-70.
27. Seyhan EC, Altin S, Cetinkaya E, et al. Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma. Ann Thorac Cardiovasc Surg 2011; 17(2): 110-117.
28. Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009; 64(1): 98-104.
29. Booton R, Ward T, Ashcroft L, et al. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007; 2(10): 902-906.
30. Zheng Z, Chen T, Li X, et al. The DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356: 800-808.
31. Friboulet L, Olaussen KA, Pignon JP, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013; 368(12): 1101-1110.
32. Siddik ZH. Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. In: The Cancer Handbook. Alison MR (Ed.). Nature Publishing Group, London, UK 2002; 1295-1313.
33. Zhang ZY, Tian X, Wu R, et al. Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev 2012; 13(6): 2583-2586.
34. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22(13): 2594-2601.
35. Yin M, Yan J, Voutsina A et al. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer 2010; 72 (3): 370377.
36. Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst 2000; 92: 440-441.
37. Avan A, Pacetti P, Reni M, et al. Prognostic factors in gemcit-abine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int J Cancer 2013. doi: 10.1002/ijc.28078. [Epub ahead of print]
38. Mohrenweiser HW, Xi T, Vazquez-Matias J, Jones IM. Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol Biomarkers Prev 2002; 11(10 Pt 1): 1054-1064.
39. Yuan P, Miao XP, Zhang XM, et al. XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Chin J Oncol 2006; 28(3): 196-199.
40. Sun X, Li F, Sun N, et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009; 65(2): 230-236.
41. Joerger M, Burgers SA, Baas P, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2012; 118(9): 2466-2475.
42. Chen J, Zhao QW, Shi GM, et al. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies. J Zhejiang Univ Sci B 2012; 13(11): 875-883.
43. Kang CH, Jang BG, Kim DW, et al. The prognostic significance of ERCC1, BRCA1, XRCC1, and pIII-tubulin expression in patients with non-small cell lung cancer treated by platinu- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 2010; 68(3): 478-483.
44. Wang X, Cui E, Zeng H, et al. RAGE Genetic Polymorphisms Are Associated with Risk, Chemotherapy Response and Prognosis in Patients with Advanced NSCLC. PLoS One 2012; 7(10): e43734.
45. Pu X, Hildebrandt MAT, Lu C, et al. PI3K/PTEN/AKT/mTOR Pathway Genetic Variation Predicts Toxicity and Distant Progression in Lung Cancer Patients Receiving Platinum-based Chemotherapy. Lung Cancer 2011; 71(1): 82-88.
46. Wang YD, Ha MW, Cheng J, et al. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC. Oncol Rep 2012; 27(4): 979-986.
47. Elnaggar M, Giovannetti E, Peters GJ. Molecular Targets of Gem-citabine Action: Rationale for Development of Novel Drugs and Drug Combinations. Curr Pharm Des 2012; 18(19): 2811-2829.
48. Achiwa H, Oguri T, Sato S, et al. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004; 95: 753-757.
49. Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66: 3928-3925.
50. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136(1): 187-195.
51. Oguri T, Achiwa H, Muramatsu H, et al. The absence of human equilibrative nucleoside transporter 1 expression predicts nonre-sponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett 2007; 256(1): 112-119.
52. Avan A, Maftouh M, Giovannetti E. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment. Cancer 2013; 119(14): 2662-2663.
53. Li L, Schaid DJ, Fridley BL, et al. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet Genomics 2012; 22(2): 105-116.
54. Danesi, G Altavilla, E Giovannetti, et al. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics 2009; 10(1): 69-80.
55. van Bree C, Castro Kreder N, Loves WJ, et al. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines. Int J Radiat Oncol Biol Phys 2002; 54: 237-244.
56. Kroep JR, Loves WJ, van der Wilt CL, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002; 1: 371-376.
57. Sève P, Mackey JR, Isaac S, et al. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer 2005; 49(3): 363-370.
58. Ryu JS, Kim HJ, Shin ES, et al. Lack of association of genetic variations of deoxycytidine kinase with toxicity or survival of non-small-cell lung cancer patients treated with gemcitabine plus cis-platin. Nam HS, Cho JH, Lee JE. Oncol Res 2012; 20(1): 25-30.
59. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008; 14: 1797-1803.
60. Tibaldi C, Giovannetti E, Tiseo M, et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann Oncol 2012; 23(3): 670-677.
61. Soo RA, Wang LZ, Ng SS, et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 2009; 63(1): 121-127.
62. Ludovini V, Floriani I, Pistola L, et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival inc isplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol 2011; 6(12): 2018-2026.
63. Sugiyama E, Kaniwa N, Kim SR, et al. Pharmacokinetics of gem-citabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25(1): 32-42.
64. Maring JG, Wachters FM, Slijfer M, et al. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol 2010; 66(6): 611-617.
65. Joerger M, Burgers JA, Baas P, et al. Gene polymorphisms, phar-macokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2012; 69(1): 25-33.
66. Joerger M, Burgers SA, Baas P, et al. Germline polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: A prospective clinical study. Cancer 2011; 118(9): 2466-2475.
67. Ciccolini J, Mercier C, Dahan L, et al. Integrating pharmacogenet-ics into gemcitabine dosing-time for a change? Nat Rev Clin Oncol 2011; 8(7): 439-444.
68. Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004; 64: 3761-3766.
69. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004; 10: 4215s-4219s.
70. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24: 4731-4737.
71. Zheng Z, Chen T, Xueli L, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356: 800-808.
72. Simon GR, Schell MJ, Begum M, et al. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. Cancer 2011; 118(9): 2525-2531.
73. Yang LY, Li L, Jiang H, et al. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 2000; 6: 773-781.
74. Peters GJ, van der Wilt CL, van Moorsel CJ, et al. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87(2-3): 227-253.
75. Bepler G, Zheng Z, Gautam A, et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 2005; 47: 183-192.
76. Dong S, Guo AL, Chen ZH, et al. RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J Hematol Oncol 2010; 3: 10.
77. Kim SO, Jeong JY, Kim MR, et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 2008; 14: 3083-3088.
78. Kwon WS, Rha SY, Choi YH, et al. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gem-citabine chemosensitivity in cancer cell lines. Pharmacogenet Ge-nomics 2006; 16: 429-438.
79. Ryu JS, Shin ES, Nam HS, et al. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or tax-ane/cisplatinum. J Thorac Oncol 2011; 6(8): 1320-1329.
80. Giovannetti E, van der Velde A, Funel N, et al. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One 2012; 7(11): e49145.
81. Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999; 17: 1786-93.
82. Rosell R, Felip E. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer. Semin Oncol 2001; 28: 37-44.
83. Monzo M, Taron M, Rosell R, Re: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst 2002; 94: 774-776.
84. Verdier-Pinard P, Wang F, Martello L, et al. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry 2003; 42: 5349-5357.
85. Ranganathan S, Benetatos CA, Colarusso PJ, et al. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998; 77: 562-566.
86. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pre-treatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene. 2003; 223: 548-553.
87. Lafarge S, Sylvain V, Ferrara M, et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001; 20: 6597-6606.
88. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275: 23899-23903.
89. Mullan PB, Quinn JE, Gilmore PM, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001; 20: 6123-6131.
90. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221-6228.
91. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy. Clin Cancer Res 2007; 13: 7413-7420.
92. Wang L, Wei J, Qian X, et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008; 8: 97.
93. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13: 2443-2449.
94. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009; 4(5): e5133.
95. Wang B, Matsuoka S, Ballif BA, et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007; 316: 1194-1198.
96. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol.Cancer Ther 2007; 6: 404-417.
97. Giovannetti E, Lemos C, Tekle C, et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitar-geted antifolate pemetrexed in non-small-cell lung cancer cells. Mol.Pharmacol 2008; 73: 1290-1300.
98. Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011; 104: 1594-1601.
99. Hanauske AR, Eismann U, Oberschmidt O, et al. In vitro che-mosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007; 25: 417-423.
100. Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed. Lung Cancer 2011; 74(1): 132-138.
101. Sun JM, Han J, Ahn JS, et al. Significance of Thymidylate Syn-thase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pe-metrexed-Based Chemotherapy. J Thorac Oncol 2011; 6(8): 1392-1399.
102. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107: 1589-1596.
103. Galvani E, Peters GJ, Giovannetti E. Thymidylate synthase inhibitors for non-small cell lung cancer. Expert Opin Investig Drugs 2011; 20(10): 1343-1356.
104. Novello S, Scagliotti G, Torri V, et al. International tailored chemotherapy adjuvant trial: ITACA trial. J Clin Oncol 2011; 29 (suppl; abstr e17514).
105. Horie N, Aiba H, Oguro K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate syn-thase. Cell Struct Funct 1995; 20: 191-197.
106. Marsh S, McKay JA, Cassidy J, et al. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001; 19: 383-386.
107. Villafranca E, Okruzhnov Y, Dominguez MA, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19: 1779-1786.
108. Jakobsen A, Nielsen JN, Gyldenkerne N, et al. Thymidylate syn-thase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365-1369.
109. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nonge-netic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-2138.
110. Wang X, Wang Y, Wang Y, et al. Association of thymidylate syn-thase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. J Biomed Sci 2013; 20: 5.
111. Li WJ, Jiang H, Fang XJ, et al. Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. Oncol Lett 2013; 5(4): 1165-1170.
112. Mauritz R, Giovannetti E, Beumer IJ, et al. Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer. Clin Colorectal Cancer 2009; 8: 146-154.
113. Hu Q, Li X, Su C, et al. Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. Exp Ther Med 2012; 4(6): 1010-1016.
114. Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 2038-2045.
115. Tiseo M, Giovannetti E, Tibaldi C, et al. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 2012; 78(1): 92-99.
116. Li WJ, Jiang H, Fang XJ, et al. Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. Oncol Lett 2013; 5(4): 1165-1170.
117. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007; 26: 153-181.
118. Stark M, Wichman C, Avivi I, et al. Aberrant splicing of folylpoly-glutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009; 113(18): 4362-4369.
119. Uemura T, Oguri T, Ozasa H, et al. ABCC11/MRP8 confers pe-metrexed resistance in lung cancer. Cancer Sci 2010; 101: 2404-2410.
120. Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pe-metrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010; 28: 614-619.
121. Adjei AA, Salavaggione OE, Mandrekar SJ, et al. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. J Thorac Oncol 2010; 5: 1346-1353.
122. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11(14): 1911-1914.
123. Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol 2003; 194(1): 13-19.
124. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004; 10(12 Pt 2): 4227s-4232s.
125. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372(9652): 1809-1818.
126. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 2005; 353(2): 123-132.
127. Mok TS, Wu YL, Thongprasert S, Yang CH, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361(10): 947-957.
128. Hartmann JT, Haap M, Kopp HG, Lipp H-P. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10(5): 470-481
129. http://www.cancer.gov/cancertopics/druginfo/fda-erlotinib-hydrochloride
130. Lee JK, Shin JY, Kim S, et al. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol 2013. [Epub ahead of print]
131. Galvani E, Alfieri R, Giovannetti E, et al. Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Curr Pharm Des 2013; 19(5): 818-832.
132. Helfrich BA, Raben D, Varella-Garcia M, et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 2006; 12(23): 7117-7125.
133. Wang S, An T, Duan J, et al. Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer. PLoS One 2013; 8(3): e51021.
134. Nomura M, Shigematsu H, Li L, et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 2007; 4(4): e125.
135. Moriai T, Kobrin MS, Hope C, Speck L, Korc M. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. P Natl Acad Sci USA 1994; 91(21): 10217-10221.
136. Liu W, Innocenti F, Wu MH, et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005; 65(1): 46-53.
137. Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2008; 8(2): 129-138.
138. Jung M, Cho BC, Lee CH, et al. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Med J 2012; 53(6): 1128-1135.
139. Ichihara S, Toyooka S, Fujiwara Y, et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer. 2007; 120(6): 1239-1247.
140. Shitara M, Sasaki H, Yokota K, et al. Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients. Exp Ther Med 2012; 4(5): 785-789.
141. Gregorc V, Hidalgo M, Spreafico A, et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther 2008; 83(3): 477-484.
142. Gebhardt F, Bürger H, Brandt B. Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations--a link between genetics and epigenetics. Histol Histopathol 2000; 15(3): 929-936.
143. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004; 64(24): 9139-9143.
144. Gebhardt F, Zänker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999; 274(19): 13176-13180.
145. Buerger H, Gebhardt F, Schmidt H, et al. Length and loss of het-erozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000; 60(4): 854-857.
146. Han S-W, Jeon YK, Lee KH, et al. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Phar-macogenet Genom 2007; 17(5): 313-319.
147. Ma F, Sun T, Shi Y, et al. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer 2009; 66(1): 114-119.
148. Dubey S, Stephenson P, Levy DE, et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 2006; 1(5): 406-412.
149. Nie Q, Wang Z, Zhang GC, et al. The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. Eur J Pharmacol 2007; 570(1-3): 175-181.
150. Tiseo M, Capelletti M, De Palma G, et al. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J Thorac Oncol 2008; 3(10): 1104-1111.
151. Tiseo M, Rossi G, Capelletti M, et al. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer 2010; 67(3): 355-360.
152. Giovannetti E, Zucali PA, Peters GJ, et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther 2010; 9(3): 581-593.
153. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29(31): 4113-4120.
154. Zhang J, Zhan Z, Wu J, et al. Association among Polymorphisms in EGFR Gene Exons, Lifestyle and Risk of Gastric Cancer with Gender Differences in Chinese Han Subjects. PLoS One 2013; 8(3): e59254.
155. Shitara M, Sasaki H, Yokota K, et al. Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients. Exp Ther Med 2012; 4(5): 785-789.
156. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer I 2004; 96(15): 1133-1141.
157. Cappuzzo F, Ligorio C, Jänne PA, et al. Prospective study of gefit-inib in epidermal growth factor receptor fluorescence in situ hy-bridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol. 2007; 25(16): 2248-2255.
158. Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of onco-genic AKT E17K mutation in common solid cancers and acute leukaemias. Brit J Cancer 2008; 98(9): 1533-1535.
159. Harris SL, Gil G, Robins H, et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. P Natl Acad Sci USA 2005; 102(45): 16297-1302.
160. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004; 36(2): 131-137.
161. Hildebrandt MAT, Yang H, Hung M-C, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradio-therapy. J Clin Oncol 2009; 27(6): 857-871.
162. Kim MJ, Kang H-G, Lee SY, et al. AKT1 polymorphisms and survival of early stage non-small cell lung cancer. J Surg Oncol 2012; 105(2): 167-174
163. Lemos C, Jansen G, Peters GJ. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Brit J Cancer 2008; 98(5): 857-862.
164. Li J, Cusatis G, Brahmer J, et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyro-sine kinase inhibitors in cancer patients. Cancer Biol Ther 2007; 6(3): 432-438.
165. Lemos C, Giovannetti E, Zucali PA, et al. Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 2011; 12(2): 159-170.
166. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23(22): 5235-5246.
167. Galvani E, Peters GJ, Giovannetti E. EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. Future Oncol 2012; 8(8): 1015-1029.
168. Huang C-L, Yang C-H, Yeh K-H, et al. EGFR intron 1 dinucleo-tide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer 2009; 64(3): 346-351.
169. Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharma-cokinetic determinants of erlotinib toxicity. J Clin Oncol 2008; 26(7): 1119-1127
170. Cusatis G, Gregorc V, Li J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer I 2006; 98(23): 1739-1742.
171. Hamada A, Sasaki J, Saeki S, et al. Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer. Pharmacogenomics 2012; 13(5): 615-624.
172. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13(12): 3731-3737.
173. Von Hoff DD, Stephenson JJ Jr., Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28: 4877-4883.
174. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative. J Clin Oncol 2011; 29(suppl). (Abstr CRA2500).
175. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1: 44-53.
176. Zhou X, Liu S, Kim ES, et al. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials 2008; 5: 181-193.
177. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput onco-gene mutation profiling in human cancer. Nat Genet 2007; 39: 347-351.
178. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. Embo Mol Med 2010; 2: 146-158.
179. Su Z, Dias-Santagata D, Duke M, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 2011; 13: 74-84.
180. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010; 11: 31-46.
181. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11: 685-696.
182. Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 2: 82.
183. Wen Y-Y, Fang E, Li Y, et al. The efficacy of targeted next-generation sequencing for detection of clinically actionable mutations in cancer. J Clin Oncol 2012; 30(suppl). (Abstr 10598).